Cognitive functioning in a cohort of high-grade glioma patients

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114: 97–109. doi: 10.1007/s00401-007-0243-4 LouisDN OhgakiH WiestlerOD CaveneeWK BurgerPC JouvetA The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 2007 114 97 109 10.1007/s00401-007-0243-4 Open DOISearch in Google Scholar

2. Smrdel U, Popovic M, Zwitter M, Bostjancic E, Zupan A, Kovac V, et al. Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. Radiol Oncol 2015; 50: 394–401. doi: 10.1515/raon-2015-0041 SmrdelU PopovicM ZwitterM BostjancicE ZupanA KovacV Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor Radiol Oncol 2015 50 394 401 10.1515/raon-2015-0041 Open DOISearch in Google Scholar

3. Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, et al. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochir 2016; 158: 1943–53. doi: 10.1007/s00701-016-2928-8 MillwardCP BrodbeltAR HaylockB ZakariaR BaborieA CrooksD The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy Acta Neurochir 2016 158 1943 53 10.1007/s00701-016-2928-8 Open DOISearch in Google Scholar

4. Kurdi M, Shafique Butt N, Baeesa S, Alghamdi B, Maghrabi Y, Bardeesi A, et al. The impact of IDH1 mutation and MGMT promoter methylation on recurrence-free interval in glioblastoma patients treated with radiotherapy and chemotherapeutic agents. Pathol Oncol Res 2021; 27: 1609778. doi: 10.3389/pore.2021.1609778 KurdiM Shafique ButtN BaeesaS AlghamdiB MaghrabiY BardeesiA The impact of IDH1 mutation and MGMT promoter methylation on recurrence-free interval in glioblastoma patients treated with radiotherapy and chemotherapeutic agents Pathol Oncol Res 2021 27 1609778 10.3389/pore.2021.1609778 Open DOISearch in Google Scholar

5. Sinha R, Stephenson JM, Price SJ. A systematic review of cognitive function in patients with glioblastoma undergoing surgery. Neuro-oncology Pract 2020; 7: 131–42. doi: 10.1093/nop/npz018 SinhaR StephensonJM PriceSJ A systematic review of cognitive function in patients with glioblastoma undergoing surgery Neuro-oncology Pract 2020 7 131 42 10.1093/nop/npz018 Open DOISearch in Google Scholar

6. Van Kessel E, Emons MAC, Wajer IH, Van Baarsen KM, Broekman ML, Robe PA, et al. Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment. Neuro-Oncology Pract 2019; 6: 463. doi: 10.1093/nop/npz008 Van KesselE EmonsMAC WajerIH Van BaarsenKM BroekmanML RobePA Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment Neuro-Oncology Pract 2019 6 463 10.1093/nop/npz008 Open DOISearch in Google Scholar

7. Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurology 2004; 3: 159–68. doi: 10.1016/S1474-4422(04)00680-5 TaphoornMJB KleinM Cognitive deficits in adult patients with brain tumours Lancet Neurology 2004 3 159 68 10.1016/S1474-4422(04)00680-5 Open DOISearch in Google Scholar

8. Jütten K, Mainz V, Gauggel S, Patel HJ, Binkofski F, Wiesmann M, et al. Diffusion tensor imaging reveals microstructural heterogeneity of normal-appearing white matter and related cognitive dysfunction in glioma patients. Front Oncol 2019; 9: 536. doi: 10.3389/fonc.2019.00536 JüttenK MainzV GauggelS PatelHJ BinkofskiF WiesmannM Diffusion tensor imaging reveals microstructural heterogeneity of normal-appearing white matter and related cognitive dysfunction in glioma patients Front Oncol 2019 9 536 10.3389/fonc.2019.00536 Open DOISearch in Google Scholar

9. Van Kessel E, Snijders TJ, Anniek ·, Baumfalk E, Ruis C, Van Baarsen KM, et al. Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study. J Neurooncol 2020; 146: 97–109. doi: 10.1007/s11060-019-03341-6 Van KesselE SnijdersTJ BaumfalkAnniek E RuisC Van BaarsenKM Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study J Neurooncol 2020 146 97 109 10.1007/s11060-019-03341-6 Open DOISearch in Google Scholar

10. Meyers CA, Hess KR. Neuro-oncology multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-Oncology2003; 5: 89–95. doi: 10.1093/neuonc/5.2.89 MeyersCA HessKR Neuro-oncology multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression Neuro-Oncology 2003 5 89 95 10.1093/neuonc/5.2.89 Open DOISearch in Google Scholar

11. Armstrong CL, Goldstein B, Shera D, Ledakis GE, Tallent EM. The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer 2003; 97: 649–56. doi: 10.1002/cncr.11099 ArmstrongCL GoldsteinB SheraD LedakisGE TallentEM The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence Cancer 2003 97 649 56 10.1002/cncr.11099 Open DOISearch in Google Scholar

12. Flechl B, Sax C, Ackerl M, Crevenna R, Woehrer A, Hainfellner J, et al. The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. Radiother Oncol 2017; 125: 228–33. doi: 10.1016/j.radonc.2017.07.027 FlechlB SaxC AckerlM CrevennaR WoehrerA HainfellnerJ The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma Radiother Oncol 2017 125 228 33 10.1016/j.radonc.2017.07.027 Open DOISearch in Google Scholar

13. Johnson DR, Sawyer AM, Meyers CA, Patrick B, Neill O’, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 2012; 14: 808–16. doi: 10.1093/neuonc/nos082 JohnsonDR SawyerAM MeyersCA O’NeillPatrick B WefelJS Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma Neuro Oncol 2012 14 808 16 10.1093/neuonc/nos082 Open DOISearch in Google Scholar

14. Meyers CA, Hess KR, Yung WKA, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000; 18: 646–50. doi: 10.1200/JCO.2000.18.3.646 MeyersCA HessKR YungWKA LevinVA Cognitive function as a predictor of survival in patients with recurrent malignant glioma J Clin Oncol 2000 18 646 50 10.1200/JCO.2000.18.3.646 Open DOISearch in Google Scholar

15. Lee ST, Park CK, Kim JW, Park MJ, Lee H, Lim JA, et al. Early cognitive function tests predict early progression in glioblastoma. Neuro-oncology Pract 2015; 2: 137–43. doi: 10.1093/nop/npv007 LeeST ParkCK KimJW ParkMJ LeeH LimJA Early cognitive function tests predict early progression in glioblastoma Neuro-oncology Pract 2015 2 137 43 10.1093/nop/npv007 Open DOISearch in Google Scholar

16. Butterbrod E, Synhaeve N, Rutten GJ, Schwabe I, Gehring K, Sitskoorn M. Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients. J Neurooncol 2020; 149: 103–11. doi: 10.1007/s11060-020-03577-7 ButterbrodE SynhaeveN RuttenGJ SchwabeI GehringK SitskoornM Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients J Neurooncol 2020 149 103 11 10.1007/s11060-020-03577-7 Open DOISearch in Google Scholar

17. Derks J, Kulik S, Wesseling P, Numan T, Hillebrand A, van Dellen E, et al. Understanding cognitive functioning in glioma patients: the relevance of IDH-mutation status and functional connectivity. Brain Behav 2019; 9: e01204.doi: 10.1002/brb3.1204 DerksJ KulikS WesselingP NumanT HillebrandA van DellenE Understanding cognitive functioning in glioma patients: the relevance of IDH-mutation status and functional connectivity Brain Behav 2019 9 e01204 10.1002/brb3.1204 Open DOISearch in Google Scholar

18. van Kessel E, Snijders TJ, Baumfalk AE, Ruis C, van Baarsen KM, Broekman ML, et al. Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study. J Neurooncol 2020; 146: 97–109. doi: 10.1007/s11060-019-03341-6 van KesselE SnijdersTJ BaumfalkAE RuisC van BaarsenKM BroekmanML Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study J Neurooncol 2020 146 97 109 10.1007/s11060-019-03341-6 Open DOISearch in Google Scholar

19. Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol 2016; 18: 1656–63. doi: 10.1093/neuonc/now165 WefelJS NollKR RaoG CahillDP Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection Neuro Oncol 2016 18 1656 63 10.1093/neuonc/now165 Open DOISearch in Google Scholar

20. Bunevicius A, Miller J, Parsons M. Isocitrate dehydrogenase, patient-reported outcomes, and cognitive functioning of glioma patients: a systematic review. Curr Oncol Rep 2020; 22: 120. doi: 10.1007/s11912-020-00978-9 BuneviciusA MillerJ ParsonsM Isocitrate dehydrogenase, patient-reported outcomes, and cognitive functioning of glioma patients: a systematic review Curr Oncol Rep 2020 22 120 10.1007/s11912-020-00978-9 Open DOISearch in Google Scholar

21. Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, et al. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2019; 20: 1444–53. doi: 10.1016/S1470-2045(19)30502-9 WellerJ TzaridisT MackF SteinbachJP SchlegelU HauP Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial Lancet Oncol 2019 20 1444 53 10.1016/S1470-2045(19)30502-9 Open DOISearch in Google Scholar

22. Wang Q, Xiao F, Qi F, Song X, Yu Y. Risk factors for cognitive impairment in high-grade glioma patients treated with postoperative radiochemotherapy. Cancer Res Treat 2020; 52: 586–93. doi: 10.4143/crt.2019.242 WangQ XiaoF QiF SongX YuY Risk factors for cognitive impairment in high-grade glioma patients treated with postoperative radiochemotherapy Cancer Res Treat 2020 52 586 93 10.4143/crt.2019.242 Open DOISearch in Google Scholar

23. Herzog A. [Validity and reliability of the new Slovenian Test of Word Learning]. [Slovenian]. [graduation thesis]. Ljubljana: Universty of Ljubljana; 2015. HerzogA [Validity and reliability of the new Slovenian Test of Word Learning]. [Slovenian]. [graduation thesis] Ljubljana Universty of Ljubljana 2015 Search in Google Scholar

24. Remšak T. [Development of the Spelling Fluency Test]. [Slovenian]. [graduation thesis]. Ljubljana: Universty of Ljubljana; 2013. RemšakT [Development of the Spelling Fluency Test]. [Slovenian]. [graduation thesis] Ljubljana Universty of Ljubljana 2013 Search in Google Scholar

25. Sánchez-Cubillo I, Periáñez JA, Adrover-Roig D, Rodríguez-Sánchez JM, Ríos-Lago M, Tirapu J, et al. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc 2009; 15: 438–50. doi: 10.1017/S1355617709090626 Sánchez-CubilloI PeriáñezJA Adrover-RoigD Rodríguez-SánchezJM Ríos-LagoM TirapuJ Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities J Int Neuropsychol Soc 2009 15 438 50 10.1017/S1355617709090626 Open DOISearch in Google Scholar

26. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011; 12: 703–8. doi: 10.1016/S1470-2045(10)70294-1 WefelJS VardyJ AhlesT SchagenSB International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer Lancet Oncol 2011 12 703 8 10.1016/S1470-2045(10)70294-1 Open DOISearch in Google Scholar

27. Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, et al. Molecular biomarker-defined brain tumors: epidemiology, validity, and completeness in the United States. Neuro Oncol 2022; 24: 1989–2000. doi: 10.1093/neuonc/noac113 IorgulescuJB SunC NeffC CioffiG GutierrezC KruchkoC Molecular biomarker-defined brain tumors: epidemiology, validity, and completeness in the United States Neuro Oncol 2022 24 1989 2000 10.1093/neuonc/noac113 Open DOISearch in Google Scholar

28. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol 2008; 115: 249–59. doi: 10.1007/s00401-007-0310-x CapperD MittelbronnM MeyermannR SchittenhelmJ Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach Acta Neuropathol 2008 115 249 59 10.1007/s00401-007-0310-x Open DOISearch in Google Scholar

29. Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 2000; 47: 324–33. doi: 10.1097/00006123-200008000-00011 TuchaO SmelyC PreierM LangeKW Cognitive deficits before treatment among patients with brain tumors Neurosurgery 2000 47 324 33 10.1097/00006123-200008000-00011 Open DOISearch in Google Scholar

30. Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neurooncol 2017; 131: 565–74. doi: 10.1007/s11060-016-2328-1 KeslerSR NollK CahillDP RaoG WefelJS The effect of IDH1 mutation on the structural connectome in malignant astrocytoma J Neurooncol 2017 131 565 74 10.1007/s11060-016-2328-1 Open DOISearch in Google Scholar

31. Van Kessel E, Snijders TJ, Anniek·, Baumfalk E, Ruis C, Van Baarsen KM, et al. Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study. J Neurooncol 2020; 146: 97–109. doi: 10.1007/s11060-019-03341-6 Van KesselE SnijdersTJ BaumfalkAnniek E RuisC Van BaarsenKM Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study J Neurooncol 2020 146 97 109 10.1007/s11060-019-03341-6 Open DOISearch in Google Scholar